Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 116 for:    medullary carcinoma

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin (CMTpostopFDOPA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02856347
Recruitment Status : Recruiting
First Posted : August 4, 2016
Last Update Posted : August 8, 2019
Sponsor:
Information provided by (Responsible Party):
Institut Claudius Regaud

Brief Summary:

The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease.

This is an inter-regional multicentric, prospective study evaluating the benefit of PET F-DOPA imaging in involved node detection compared to standard imaging assessment in patient with medullary thyroid cancer.

The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging.

Obtained data will be compared to the "gold standard" based on :

  • nodes cytology when they could be punctured
  • histology when a new surgery will be recommended
  • surveillance when the 2 first cases will be not applicable (imaging monitoring, evolution of thyrocalcitonin)

Condition or disease Intervention/treatment Phase
Medullary Thyroid Cancer Other: 18F-DOPA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Actual Study Start Date : March 22, 2017
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021


Arm Intervention/treatment
PET 18-FDOPA

18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).

PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).

Other series of images will be done 50 min after tracer injection. Images will be interpreted.

Other: 18F-DOPA
Injection of 18F-DOPA and PET / CT-scan assessment




Primary Outcome Measures :
  1. Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment. [ Time Frame: up to 3 years ]
    Analysis will be performed by node.


Secondary Outcome Measures :
  1. Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment. [ Time Frame: up to 3 years ]
    Analysis will be performed by patient.

  2. Relative rate of FALSE positive nodes with PET F-DOPA compared to standard imaging assessment. [ Time Frame: up to 3 years ]
    Analyses will be performed by patient and by node.

  3. Relative rate of TRUE positive and FALSE metastasis with PET F-DOPA compared to standard imaging assessment. [ Time Frame: up to 3 years ]
    Analyses will be performed by patient and by metastasis.

  4. Modification rate of patient's care after PET F-DOPA exam. [ Time Frame: up to 3 years ]
    Comparison of the modification of care (orientation to a surgery or a surveillance) decided after standard imaging assessment following result of TEP-FDOPA exam.

  5. The concordance between the PET F-DOPA results of each centre and centralized review. [ Time Frame: up to 3 years ]
    Concordance (centre / reviewer) of PET F-DOPA result interpretation will be evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > or = 18 years.
  2. Patient with medullary thyroid cancer (sporadic or hereditary form).
  3. Patient treated by total thyroidectomy with uni or bi-lateral lymph node dissection (in the central and/or lateral neck compartment).
  4. Patient with elevated thyrocalcitonin rate > or = 150 pg/ml assessed within 6 weeks or more after surgery.
  5. Patient with standard imaging assessment performed during 3 months before PET 18-FDOPA.
  6. Standard imaging assessment including at least a cervical ultra-sound, a cervico-thoracic CT-scan and/or a cervico-thoraco-abdomino-pelvic CT-scan and a liver MRI.
  7. Patient able to be followed at least 6 months after PET 18-FDOPA.
  8. If women are breastfeeding, nursing should be discontinued during 24 hours after PET 18-FDOPA.
  9. Patient must provide written informed consent prior to any specific procedure or assessment.
  10. Patient must be affiliated to the French Social Security System.

Exclusion Criteria:

  1. Pregnant patient.
  2. Post-operative radiotherapy initiated before PET 18-FDOPA.
  3. Patient with PET 18-FDG performed within 24 hours before PET 18-FDOPA.
  4. Participation in any other clinical trial for therapeutic use.
  5. Patient with PET / CT-scan exam contra-indication.
  6. Any serious and/or unstable pre-existing psychological, familial, geographic or social condition that could interfere with medical follow-up and compliance to study procedures.
  7. Patient protected by law.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02856347


Contacts
Layout table for location contacts
Contact: Slimane Zerdoud, MD 0033 05 31 15 56 28 zerdoud.slimane@iuct-oncopole.fr

Locations
Layout table for location information
France
CHU Haut-Lévêque Recruiting
Bordeaux, France
Contact: Elif Hindie, MD    +33 05 57 65 64 08    Elif.hindie@chu-bordeaux.fr   
Principal Investigator: Elif Hindie, MD         
CHU Limoges Recruiting
Limoges, France
Contact: Jacques Monteil, MD       jaques.monteil@unilim.fr   
Principal Investigator: Jacques Monteil, MD         
CHU Timone Recruiting
Marseille, France
Contact: David Taïeb, MD    +33 04 91 38 44 06    David.taieb@ap-hm.fr   
Principal Investigator: David Taïeb, MD         
ICM Montpellier Recruiting
Montpellier, France
Contact: Marie-Claude Eberle, MD    +33 04 67 61 85 82    Marie-Claude.Eberle@icm.unicancer.fr   
Principal Investigator: Marie-Claude Eberle, MD         
Institut Claudius Regaud Recruiting
Toulouse, France, 31059
Contact: Slimane Zerdoud, MD    +33 5 31 15 52 70    zerdoud.slimane@iuct-oncopole.fr   
Principal Investigator: Slimane Zerdoud, MD         
Sponsors and Collaborators
Institut Claudius Regaud
Investigators
Layout table for investigator information
Principal Investigator: Slimane Zerdoud, MD Institut Claudius Regaud

Layout table for additonal information
Responsible Party: Institut Claudius Regaud
ClinicalTrials.gov Identifier: NCT02856347     History of Changes
Other Study ID Numbers: 16VADS03
First Posted: August 4, 2016    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Claudius Regaud:
Medullary Thyroid Cancer
PET F-DOPA
18-FDOPA
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Neuroendocrine
Carcinoma
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Calcitonin
Salmon calcitonin
Dihydroxyphenylalanine
Elcatonin
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents